Brief: Sensei Biotherapeutics Presents Preclinical Data for SNS-101 at SITC 36th Annual Meeting
12/11/2021 12:31
Nov 12 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS PRESENTS PRECLINICAL DATA FOR
SNS-101, A
PH-SELECTIVE ANTI-VISTA ANTIBODY, AT THE SOCIETY FOR
IMMUNOTHERAPY OF CANCER (SITC) 36TH ANNUAL MEETING
* SENSEI BIOTHERAPEUTICS INC - IND-ENABLING STUDIES UNDERWAY
FOR
SNS-101
Source text for Eikon: ID:nGNX6Z60Sv
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)